List of largest pharmaceutical companies by revenue

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

The following is a list of the top independent pharmaceutical & biotechnology companies ranked by their revenue generated ($10 billion) in the respective financial year, it does not include biotechnology companies that are now owned by, or part of, larger pharmaceutical groups.

The change is the companies relative position in this list, compared to their relative position in the prior year; i.e., an increase would be moving closer to rank 1 and vice versa. Green cells indicate years where revenue increased compared to the previous year, red cells indicate those years where there has been a decrease.

Top pharmaceutical companies with revenue greater than $10 billion[edit]

Rank Chg Company 2018
USD billions
2017
USD billions
2016
USD billions
2015
USD billions
2014
USD billions
2013
USD billions
2012
USD billions
2011
USD billions
1 Steady United States Johnson & Johnson
NYSEJNJ
40.81 (Q2)[1] 76.50[2] 71.89[3] 70.10[4] 74.30[5] 71.31[6] 67.20[7] 65.00[8]
2 Steady Switzerland Roche
OTCQXRHHBY
28.30 (Q2)[9] 57.37[10] 50.11[11] 47.70[12] 49.86[13] 48.53[14] 47.80[15] 45.21[16]
3 Steady United States Pfizer
NYSEPFE
26.37 (Q2)[17] 52.54[18] 52.82[19] 48.85[20] 49.61[21] 51.58[22] 58.99[23] 65.26[24]
4 Steady Switzerland Novartis
NYSENVS
25.85 (Q2)[25] 49.11[26] 48.52[27] 49.41[28] 58.00[29] 57.36[30] 56.67[31] 58.57[32]
5 Increase 1 Germany Bayer
FWBBAYN
10.83 (Q1)[33] 27.76[34] 25.27[35] 24.09[36] 25.47[37] 24.17[38] 24.30[39] 23.11[40]
6 Steady United Kingdom GlaxoSmithKline
LSEGSK
19.74 (Q2)[41] 42.05[42] 34.79[43] 29.84[44] 37.96[45] 41.61[46] 39.93[47] 41.39[48]
7 Steady United States Merck & Co.
NYSEMRK
20.51 (Q2)[49] 40.10[50] 39.80[51] 39.50[52] 42.24[53] 44.03[54] 47.27[55] 48.05[56]
8 Decrease 3 France Sanofi
NYSESNY
14.23 (Q2)[57] 42.91[58] 36.57[59] 36.73[60] 43.07[61] 42.08[62] 46.41[63] 44.34[64]
9 Steady United States AbbVie
NYSEABBV
16.21 (Q2)[65] 28.22[66] 25.56[67] 22.82[68] 19.96[69] 18.79[70]
10 Steady United States Abbott Laboratories
NASDAQABT
15.16 (Q2)[71] 27.39[72] 20.85[73] 20.41[74] 20.25[75] 21.85[76] 39.87[77] 38.85[78]
11 Steady United States Eli Lilly & Co
NYSELLY
14.08 (Q2)[79] 22.90[80] 21.22[81] 20.00[82] 19.62[83] 23.11[84] 22.60[85] 24.29[86]
12 Steady United States Amgen
NASDAQAMGN
11.61 (Q2)[87] 22.80[88] 22.99[89] 21.66[90] 20.06[91] 18.68[92] 17.30[93] 15.58[94]
13 Increase 4 United States Bristol-Myers Squibb
NASDAQBMY
10.90 (Q2)[95] 20.80[96] 19.43[97] 16.56[98] 15.88[99] 16.39[100] 17.62[101] 21.24[102]
14 Decrease 1 United Kingdom AstraZeneca
LSEAZN
10.33 (Q2)[103] 22.47[104] 23.00[105] 24.71[106] 26.10[107] 25.71[108] 27.97[109] 33.59[110]
15 Decrease 1 United States Gilead Sciences
NASDAQGILD
10.54 (Q2)[111] 25.70[112] 30.39[113] 32.15[114] 24.47[115] 10.80[116] 9.70[117] 8.39[118]
16 Decrease 1 Israel Teva Pharmaceutical Industries
NASDAQTEVA
5.07 (Q1)[119] 22.40[120] 21.90[121] 20.00[122] 20.27[123] 20.31[124] 18.31[125] 16.12[126]
17 Decrease 1 Germany Boehringer Ingelheim
Private
21.67[127] 17.54[128] 16.41[128] 17.70[128] 18.68[128] 18.89[128] 18.34[128]
18 Increase 1 Germany Merck Group
ETR: MRK
4.55(Q1)[129] 18.70[130] 16.62[131] 14.25[132] 15.29[133] 14.73[134] 14.36[135] 14.31[136]
19 Decrease 1 Denmark Novo Nordisk
NYSENVO
4.34 (Q1)[137] 18.77[138] 16.61[139] 16.06[140] 15.83[141] 14.88[142] 13.48[143] 11.56[144]
20 Steady Republic of Ireland Allergan plc
NYSEAGN
7.79 (Q2)[145] 15.94[146] 14.57[146] 15.07[146] 12.88[147] 8.68[148] 5.91[149] 4.58[150]
20 Steady Japan Takeda Pharmaceutical
TYO: 4502
16.70[151] 15.96 14.93 16.84 17.36 18.91 17.80
21 Steady Republic of Ireland Shire
NASDAQSHPG
3.77 (Q1)[152] 14.40[153] 11.40[154] 6.42[155] 6.00[156] 4.76[157] 4.68[158] 3.50[159]
22 Steady United States Celgene
NASDAQCELG
7.34 (Q2)[160]
23 Steady United States Biogen
NASDAQBIIB
3.13 (Q1)[161] 12.30[162] 11.40[163] 10.80[164] 9.70[165] 6.90[166] 5.50[167] 5.00[168]

See also[edit]

References[edit]

  1. ^ Johnson, Johnson &. "Johnson & Johnson Reports 2018 First-Quarter Results:". www.prnewswire.com. 
  2. ^ "Johnson & Johnson Reports 2017 Fourth-Quarter Results: - Johnson & Johnson". www.jnj.com. 
  3. ^ "Johnson & Johnson Reports 2016 Fourth-Quarter Results - Johnson & Johnson". www.jnj.com. 
  4. ^ "Johnson & Johnson Reports 2015 Fourth-Quarter Results:". 
  5. ^ "Johnson & Johnson Reports 2014 Fourth-Quarter and Full-Year Results - Johnson & Johnson". www.jnj.com. 
  6. ^ "Johnson & Johnson Reports 2013 Fourth-Quarter and Full-Year Results - Johnson & Johnson". www.jnj.com. 
  7. ^ "Johnson & Johnson Reports 2012 Fourth-Quarter and Full-Year Results:". 
  8. ^ "Johnson & Johnson Reports 2011 Fourth-Quarter and Full-Year Results:". 
  9. ^ https://www.fiercepharma.com/pharma/roche-ups-2018-guidance-again-as-ocrevus-steams-pass-blockbuster-threshold
  10. ^ "Roche reports good results in 2017". www.roche.com. 
  11. ^ https://www.roche.com/dam/jcr:ee2f197f-5487-4629-9e28-66b77c9cbbab/en/ar16e.pdf
  12. ^ https://www.roche.com/dam/jcr:9b36e11d-495c-42f5-b757-e80c4e88d793/en/gb15e.pdf
  13. ^ https://www.roche.com/dam/jcr:880b44a1-3fd6-4e66-bf10-f4af1e724d4d/en/gb14e.pdf
  14. ^ https://www.roche.com/dam/jcr:64fd6b2d-1a76-467f-badd-ab94b85b6d70/en/gb13e.pdf
  15. ^ https://www.roche.com/dam/jcr:3e048249-e3ce-4969-a77e-cc90d8f3fa73/en/gb12e.pdf
  16. ^ https://www.roche.com/dam/jcr:52174b39-feab-4210-82f6-9b8786a69ecf/en/gb11e.pdf
  17. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2018/q2/Q2-2018-PFE-Earnings-Release.pdf
  18. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Quarterly/2017/Q4_2017_PFE_Earnings_Release.pdf
  19. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2016/2016-financial-report.pdf
  20. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2015/2015_Pfizer_Financial_Report.pdf
  21. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2014/2014_Pfizer_Financial_Report.pdf
  22. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2013/FinancialReport2013.pdf
  23. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2012/financial2012.pdf
  24. ^ https://s21.q4cdn.com/317678438/files/doc_financials/Annual/2011/financial2011.pdf
  25. ^ https://www.novartis.com/sites/www.novartis.com/files/q2-2018-media-release-en.pdf
  26. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2017-en.pdf
  27. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2016-en.pdf
  28. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2015-en.pdf
  29. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2014-en.pdf
  30. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2013-en.pdf
  31. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2012-en.pdf
  32. ^ https://www.novartis.com/sites/www.novartis.com/files/novartis-annual-report-2011-en.pdf
  33. ^ https://www.bayer.com/en/q1-2018-en.pdfx?forced=true
  34. ^ http://www.annualreport2017.bayer.com/servicepages/downloads/files/bayer_ar17_entire.pdf
  35. ^ http://www.annualreport2016.bayer.com/servicepages/downloads/files/bayer_ar16_entire.pdf
  36. ^ http://www.annualreport2015.bayer.com/servicepages/downloads/files/entire_bayer_ar15.pdf
  37. ^ http://www.annualreport2014.bayer.com/en/bayer-annual-report-augmented-version-2014.pdfx
  38. ^ https://www.bayer.com/en/ar-2013.pdfx
  39. ^ https://www.bayer.com/en/ar-2012.pdfx
  40. ^ https://www.bayer.com/en/ar-2011.pdfx
  41. ^ https://www.gsk.com/media/5011/q2-2018-results-and-rd-update-announcement.pdf
  42. ^ https://www.gsk.com/media/4629/fy-2017-results-announcement.pdf
  43. ^ https://www.gsk.com/media/3609/annual-report-2016.pdf
  44. ^ https://www.gsk.com/media/2718/gsk-annual-report-2016.pdf
  45. ^ https://www.gsk.com/media/2710/gsk-annual-report-2014-interactive.pdf
  46. ^ https://www.gsk.com/media/2701/annual-report-2013-interactive.pdf
  47. ^ https://www.gsk.com/media/2694/annual-report-2012.pdf
  48. ^ https://www.gsk.com/media/2696/annual-report-2011.pdf
  49. ^ http://investors.merck.com/news/press-release-details/2018/Merck-Announces-Second-Quarter-2018-Financial-Results/default.aspx
  50. ^ LaVito, Angelica (2 February 2018). "Merck posts mixed fourth-quarter results as Keytruda sales skyrocket". 
  51. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2017/Q4/merck-q4-10k.pdf
  52. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2015/annual/MRK_2015_Form_10-K_FINAL_r879.pdf
  53. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2014/annual/2014-Form-10-K_FINAL_022715.pdf
  54. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2013/annual/MRK_2013_Form_10_K_FINAL_022714.pdf
  55. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2012/annual/MRK_form_10_k_2012.pdf
  56. ^ http://s21.q4cdn.com/488056881/files/doc_financials/2011/annual/form-10-k-2011.pdf
  57. ^ http://mediaroom.sanofi.com/first-quarter-2018-business-eps1-up-1-4-at-cer/
  58. ^ https://www.sanofi.com/media/Project/One-Sanofi-Web/sanofi-com/en/investors/docs/press-releases/Press_release_Q4_FY_2017.pdf
  59. ^ https://en.sanofi.com/Images/49288_20-F_2016.pdf
  60. ^ https://en.sanofi.com/Images/45889_Sanofi_20-F_2015_V2.pdf
  61. ^ https://en.sanofi.com/Images/38473_Sanofi_20-F_2014.pdf
  62. ^ https://en.sanofi.com/Images/35795_20F_SANOFI_2013.pdf
  63. ^ https://en.sanofi.com/Images/31972_20-F_2012_V2.pdf
  64. ^ https://en.sanofi.com/Images/29804_20F_2011.pdf
  65. ^ https://news.abbvie.com/news/abbvie-reports-second-quarter-2018-financial-results.htm
  66. ^ "Financial Release - AbbVie". investors.abbvie.com. 
  67. ^ "Financial Release - AbbVie". investors.abbvie.com. 
  68. ^ "Financial Release - AbbVie". investors.abbvie.com. 
  69. ^ "Financial Release - AbbVie". investors.abbvie.com. 
  70. ^ "Financial Release - AbbVie". investors.abbvie.com. 
  71. ^ Mishra, Manas. http://www.abbottinvestor.com/static-files/9b97c378-cb63-402a-bbd9-cde779dc342e.  Missing or empty |title= (help)
  72. ^ Abbott. "Abbott Reports Fourth-Quarter 2017 Results". www.prnewswire.com. 
  73. ^ Abbott. "Abbott Reports Fourth-Quarter 2016 Results". www.prnewswire.com. 
  74. ^ "Abbott Reports Fourth-Quarter 2015 Results". 
  75. ^ "Abbott Reports Fourth-Quarter 2014 Results". 
  76. ^ Abbott. "Abbott Reports Fourth-Quarter and Full-Year 2013 Results". www.prnewswire.com. 
  77. ^ "Abbott Reports Fourth-Quarter and Full-Year 2012 Results". 
  78. ^ "Abbott Hosts Conference Call for Fourth-Quarter and Full-Year 2011 Earnings - FiercePharma". www.fiercepharma.com. 
  79. ^ https://investor.lilly.com/static-files/8565700a-203e-4c17-8be3-748cc76e4762
  80. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x970018/15B962F7-AF5A-4FFA-BE13-42206D3A0820/Q4_2017_PressRelease.pdf
  81. ^ "Lilly Reports Fourth-Quarter and Full-Year 2016 Results (NYSE:LLY)". investor.lilly.com. 
  82. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x871993/5BE670A3-2B82-4876-8471-CA6BC3BD49F8/Lilly_Q4_2015_Press_Release.pdf
  83. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x806120/8637C572-31C4-402E-A179-5E107A5366B2/Q414_Lilly_Sales_and_Earnings_Press_Release.pdf
  84. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x721860/2DB60538-94FE-4E96-98D2-DA72CC301EA0/Q413%20Lilly%20Sales%20and%20Earnings%20Press%20Release.pdf
  85. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x631117/85679233-E13C-4FE7-9431-E97EFFDA6D5D/Q412%20Lilly%20Sales%20and%20Earnings%20Press%20Release.pdf
  86. ^ http://files.shareholder.com/downloads/LLY/5951368162x0x538046/24A15621-7850-45EC-8E20-30535C3D9FC9/Q411_Lilly_Sales_and_Earnings_Press_Release.pdf
  87. ^ http://investors.amgen.com/phoenix.zhtml?c=61656&p=irol-newsArticle&id=2360351
  88. ^ "Amgen Reports Fourth Quarter And Full Year 2017 Financial Results". www.amgen.com. 
  89. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjY1NTQ1fENoaWxkSUQ9MzczMzk1fFR5cGU9MQ==&t=1
  90. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjI2OTYzfENoaWxkSUQ9MzI5ODc3fFR5cGU9MQ==&t=1
  91. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTc0NTMzfENoaWxkSUQ9Mjc3NjczfFR5cGU9MQ==&t=1
  92. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM3Nzc3fENoaWxkSUQ9MjI2ODE2fFR5cGU9MQ==&t=1
  93. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDk5NjQxfENoaWxkSUQ9NTM5NDU4fFR5cGU9MQ==&t=1
  94. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTM0MzEzfENoaWxkSUQ9LTF8VHlwZT0z&t=1
  95. ^ https://www.businesswire.com/news/home/20180726005150/en/Bristol-Myers-Squibb-Reports-Quarter-Financial-Results
  96. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year Financial Results". investors.bms.com. 
  97. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2016 Financial Results - BMS Newsroom". news.bms.com. 
  98. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2015 Financial Results - BMS Newsroom". news.bms.com. 
  99. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2014 Financial Results - BMS Newsroom". news.bms.com. 
  100. ^ "Bristol-Myers Squibb Reports Fourth Quarter and Full Year 2013 Financial Results - BMS Newsroom". news.bms.com. 
  101. ^ https://s21.q4cdn.com/104148044/files/doc_financials/annual_reports/Bristol-Myers-Squibb-2012AR-lr.pdf
  102. ^ https://s21.q4cdn.com/104148044/files/doc_financials/annual_reports/BristolMyersSquibb-2011-AnnualReport.pdf
  103. ^ https://www.astrazeneca.com/content/dam/az/PDF/2018/h1-2018/H1%202018%20Results%20announcement.pdf
  104. ^ https://www.astrazeneca.com/content/dam/az/PDF/2017/Full-Year/Full-Year%202017%20Results%20announcement%20.pdf
  105. ^ https://www.astrazeneca.com/content/dam/az/PDF/Full_year_and_q4_2016_results/Full_Year_and_Q4_2016_Results_announcement.pdf
  106. ^ "Full-Year and Q4 2015 Results". www.astrazeneca.com. 
  107. ^ "AstraZeneca PLC fourth quarter and full year results 2014". www.astrazeneca.com. 
  108. ^ "AstraZeneca PLC fourth quarter and full year results 2013 - AstraZeneca". www.astrazeneca.com. 
  109. ^ "AstraZeneca PLC Fourth quarter and full year results 2012". www.astrazeneca.com. 
  110. ^ "AstraZeneca PLC Fourth quarter and full year results 2011". www.astrazeneca.com. 
  111. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDA4OTU2fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636680582523475446
  112. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mzk3OTQ3fENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636534633626809804
  113. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mzc2MjEyfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=636292722140277375
  114. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MzI4OTExfENoaWxkSUQ9LTF8VHlwZT0z&t=1&cb=635944333723565434
  115. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9Mjc3NTQ3fENoaWxkSUQ9LTF8VHlwZT0z&t=1
  116. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MjI3MDc1fENoaWxkSUQ9LTF8VHlwZT0z&t=1
  117. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTc2OTgyfENoaWxkSUQ9LTF8VHlwZT0z&t=1
  118. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTMxNzQ1fENoaWxkSUQ9LTF8VHlwZT0z&t=1
  119. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NjkzMjIxfENoaWxkSUQ9NDA0NDQwfFR5cGU9MQ==&t=1
  120. ^ "Teva Reports 2017 Full Year and Fourth Quarter Financial Results". 
  121. ^ http://www.tevapharm.com/news/teva_reports_full_year_and_fourth_quarter_2016_financial_results_02_17.aspx
  122. ^ http://www.tevapharm.com/news/teva_reports_full_year_2015_and_fourth_quarter_financial_results_02_16.aspx
  123. ^ "Teva Reports Fourth Quarter and Full Year 2014 Results". www.tevapharm.com. 
  124. ^ http://www.tevapharm.com/news/teva_reports_fourth_quarter_and_full_year_2013_results_02_14.aspx
  125. ^ http://www.tevapharm.com/news/teva_reports_fourth_quarter_and_full_year_2012_results_02_13.aspx
  126. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTI2NDkwfENoaWxkSUQ9LTF8VHlwZT0z&t=1
  127. ^ "Boehringer Ingelheim 2017 Annual Report" (PDF). www.boehringer-ingelheim.com. 
  128. ^ a b c d e f "Boehringer Ingelheim total revenue 2007-2017 - Statistic". Statista. 
  129. ^ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2018-q1/en/2018-Q1-Report-EN.pdf
  130. ^ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2017-q4/en/2017-Q4-Report-EN.pdf
  131. ^ http://ar2016.merckgroup.com/sites/default/files/downloads/en/merck_annual_report_2016.pdf
  132. ^ http://ar2015.emdgroup.com/sites/default/files/downloads/emd/Merck_GB2015_EN.pdf
  133. ^ http://ar2014.merckgroup.com/sites/default/files/downloads/en/Merck_GB2014_EN.pdf
  134. ^ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2013-q4/en/2013-AR-EN.pdf
  135. ^ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2012-q4/en/2012-AR-EN.pdf
  136. ^ https://www.merckgroup.com/content/dam/web/corporate/non-images/investors/reports-and-financials/earnings-materials/2011-q4/en/2011-Merck-Annual-Report-EN.pdf
  137. ^ https://www.novonordisk.com/media/news-details.2189261.html
  138. ^ "News details". www.novonordisk.com. 
  139. ^ https://www.novonordisk.com/content/dam/Denmark/HQ/investors/irmaterial/quarterly_financial_reports/2017/20170202_Financial%20statement_FY%202016_UK.pdf
  140. ^ Transcripts, SA (3 February 2016). "Novo Nordisk's (NVO) CEO Lars Rebien Sorensen on Q4 2015 Results - Earnings Call Transcript". 
  141. ^ Transcripts, SA (30 January 2015). "Novo Nordisk's (NVO) CEO Lars Sorensen on Q4 2014 Results - Earnings Call Transcript". 
  142. ^ Transcripts, SA (31 January 2014). "Novo Nordisk A/S Management Discusses Q4 2013 Results - Earnings Call Transcript". 
  143. ^ Transcripts, SA (31 January 2013). "Novo Nordisk's CEO Discusses Q4 2012 Results - Earnings Call Transcript". 
  144. ^ http://www.novonordisk.co.uk/content/dam/Denmark/HQ/Commons/documents/Novo-Nordisk-AR-2011-en.pdf
  145. ^ http://phx.corporate-ir.net/External.File?t=1&item=VHlwZT0yfFBhcmVudElEPTUyNzI0NDZ8Q2hpbGRJRD02OTc4MDc=
  146. ^ a b c https://www.allergan.com/news/news/thomson-reuters/allergan-reports-solid-finish-to-2017
  147. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTczMDc2fENoaWxkSUQ9Mjc1MzEzfFR5cGU9MQ==&t=1
  148. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NTM5MDk2fENoaWxkSUQ9MjI4NjI0fFR5cGU9MQ==&t=1
  149. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9MTc3MTM2fENoaWxkSUQ9LTF8VHlwZT0z&t=1
  150. ^ http://phx.corporate-ir.net/External.File?item=UGFyZW50SUQ9NDYwMzczfENoaWxkSUQ9NDg4Mzk1fFR5cGU9MQ==&t=1
  151. ^ https://www.takeda.com/newsroom/newsreleases/2018/takeda-reports-fy2017-full-year-results-and-issues-fy2018-guidance/
  152. ^ "Shire Delivers 7% Product Sales Growth and Robust Pipeline Progress in Q1 2018". www.shire.com. 
  153. ^ "Shire reports 8% pro forma product sales and strong earnings growth resulting in record operating cash flow for full year 2017". www.shire.com. 
  154. ^ http://investors.shire.com/~/media/Files/S/Shire-IR/quarterly-reports/2017/full-year-2016-results.pdf
  155. ^ http://investors.shire.com/~/media/Files/S/Shire-IR/annual-report-2015/shire-annual-report-2015.pdf
  156. ^ http://investors.shire.com/~/media/Files/S/Shire-IR/events/year-2015/1fy-2014-earnings-presentation-final-12-feb-2015.pdf
  157. ^ http://ar2013.shire.com/downloads/Shire_Annual_report_2013_financial_statements.pdf
  158. ^ "Shire Delivers Strong 2012 Results and Reiterates Confidence in 2013". investors.shire.com. 
  159. ^ http://investors.shire.com/~/media/Files/S/Shire-IR/annual-interim-reports/year-2011/annualreport2010170311.pdf
  160. ^ http://ir.celgene.com/releasedetail.cfm?ReleaseID=1073027
  161. ^ Research, Zacks Investment. "Biogen (BIIB) Q1 Earnings Beat, Sales Miss". 
  162. ^ "Biogen's Spinraza: Great Launch, Rough Ride". 25 January 2018 – via www.bloomberg.com. 
  163. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_Annual_Report_2016_on_Form_10K.pdf
  164. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_Annual_Report_2015_on_Form_10K.pdf
  165. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/Biogen_2014_Annual_Report_Web.pdf
  166. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/BiogenIdec_AR_2013.pdf
  167. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/BiogenIdec_AR_2012.pdf
  168. ^ http://investors.biogen.com/sites/biogen.investorhq.businesswire.com/files/doc_library/file/2011ar.pdf

External links[edit]